- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1741-7015
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Targeting molecular resistance in castration-resistant prostate cancer ; volume:13 ; number:1 ; day:1 ; month:9 ; year:2015 ; pages:1-10 ; date:12.2015
BMC medicine ; 13, Heft 1 (1.9.2015), 1-10, 12.2015
- Urheber
-
Chandrasekar, Thenappan
- Beteiligte Personen und Organisationen
-
Yang, Joy C.
Gao, Allen C.
Evans, Christopher P.
SpringerLink (Online service)
- DOI
-
10.1186/s12916-015-0457-6
- URN
-
urn:nbn:de:1111-201611045867
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chandrasekar, Thenappan
- Yang, Joy C.
- Gao, Allen C.
- Evans, Christopher P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Targeting SOX4/PCK2 signaling suppresses neuroendocrine trans-differentiation of castration-resistant prostate cancer
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Targeting SOX4/PCK2 signaling suppresses neuroendocrine trans-differentiation of castration-resistant prostate cancer
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Targeting SOX4/PCK2 signaling suppresses neuroendocrine trans-differentiation of castration-resistant prostate cancer
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chromogranin A: a useful biomarker in castration-resistant prostate cancer